✦ LIBER ✦

A placebo-controlled, double-blind trial of the selective AB-42 lowering agent, flurizan (MPC-7869, (R)-flurbiprofen) in patients with mild to moderate Alzheimer’s disease

✍ Scribed by Gordon K. Wilcock; Sandra Black; Judy Haworth; Mark Laughlin; Suzanne Hendrix; Mary-Helen Binger; Kenton Zavitz; Edward Swabb; Adrian Hobden

Book ID: 118461959
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 49 KB
Volume: 1
Category: Article
ISSN: 1552-5260
DOI: 10.1016/j.jalz.2005.06.330

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Melissa officinalis extract in the treat

Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial

✍ Akhondzadeh, S 📂 Article 📅 2003 🏛 BMJ Publishing Group 🌐 English ⚖ 224 KB

Results from CONNECTION: A global, Phase

Results from CONNECTION: A global, Phase 3 double-blind, placebo-controlled confirmatory trial of dimebon (latrepirdine) in patients with mild-to-moderate Alzheimer's disease

✍ Rachelle S. Doody; Pierre Tariot; Jeff Cummings; Bengt Winblad; Bryan Selby; And 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 44 KB

A long-term, double-blind, placebo-contr

A long-term, double-blind, placebo-controlled efficacy and safety study of nicergoline in patients with mild to moderate Alzheimer's disease

✍ L. Amaducci; K. Maurer; B. Winblad; R. Dom; R. Bullock; L. Bonura; A. Battaglia; 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 291 KB

A 24-week, double-blind, placebo-control

A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease

✍ X. A. Alvarez; R. Cacabelos; M. Laredo; V. Couceiro; C. Sampedro; M. Varela; L. 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 309 KB

Saffron in the treatment of patients wit

Saffron in the treatment of patients with mild to moderate Alzheimer’s disease: a 16-week, randomized and placebo-controlled trial

✍ S. Akhondzadeh; M. Shafiee Sabet; M. H. Harirchian; M. Togha; H. Cheraghmakani; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

A multicentre, randomized, double-blind,

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study

✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre